Geron Corp
GERN·Stocks·Biotechnology·United States·Nasdaq·USD
Price
Unknown
Today
+0.4%
YTD
-5.4%
About
With headquarters in Menlo Park, California, Geron develops and commercialises therapeutics to supress the proliferation of malignant cells. The company holds the rights for the drug imetelstat. Operating within the US, the company was founded in 1990. The company's stock is listed on the NASDAQ GS stock exchange using the GERN ticker. Add this stock to your eToro watchlist to get the latest news on GERN stock.
Price chart
Closing price history for GERN (1D candles).
Open positions
Current open positions for this instrument from your live portfolio.
Open positions
0
Unrealized return
+0.0%
No open positions exist for this instrument at the moment.
Financial insights
Valuation
P/E (TTM)-11.57
P/S (TTM)3.97
P/B (TTM)3.56
Market cap$777.39M
Cap tierSmall-cap
Industry avg P/E-2.16
Profitability
Gross margin96.45%
EBIT margin-18.36%
Net margin-29.02%
ROE-29.24%
ROA-13.01%
Earnings & Revenue
Revenue (TTM)$204.56M
Revenue growth (1Y)+24.4%
EPS (TTM)-$0.10
Free cash flow$-114.76M
Total debt$251.77M
Dividends & Risk
Dividend rate$0.00
Dividend yield0.00%
Beta (5Y)1.19
Employees258
Next earnings4 Nov '26
Trade history
Closed trades
0
Realized return
+0.0%
No stored closed trades exist for this instrument yet.